Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

NCT00687765 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00687765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00687765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2008
Completion date
June 30, 2015
Enrollment
126 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma